


GF Xinde and Bay City Capital Co-Host Investment Conference and Announce Collaboration on Unique Fund | ASIA TODAY News & Events















Â 

























 



 
 
 





 



 

PR NEWS


EVENTS

FEATURES

ECO & GREEN

EDUCATION

NONPROFIT

INNOVATION
 Â 


Log In

 Register







 



 Â  Â  Â EVENT Â 

 Listings
Â 
 Partners

Â 
 Newsletters
Â 
 Subscribe
Â 
 Submit Event
Â 
 Submit News
Â 





Search this site: 










Â 





 
 


 









GF Xinde and Bay City Capital Co-Host Investment Conference and Announce Collaboration on Unique Fund          





Â 












Jul 14, 2017



            Category: InvestmentPR News






















GF Securities, GF Xinde Investment Management Co., Ltd. ("GF Xinde") and Bay City Capital, LLC ("Bay City Capital"), in collaboration with the China Society of Biotechnology and the China Pharmaceutical Enterprises Development Promote Association, organized and hosted the 10th China Biotechnology Industry Conference - the Biomedical and Health Industry Investment and Financing Summit Forum. The conference was held on July 3 and 4 in the Guangzhou Baiyun International Convention Center in Guangzhou City, China.
The theme of the conference focused on the "Globalization of China's innovation and the Internationalization of regulation" in the biotechnology and biomedical industries. In addition, the conference covered the latest trends on cross-border biomedical investments and financings and bridging the technology gap between western technologies and domestic Chinese innovation.
Dr. Zeng Hao, Chairman of GF Xinde, Zhu Xun, Director of the Tongxieyi Innovative Drug Club, and David Beier JD, the Managing Director of Bay City Capital, were in attendance at the conference.
During the two-day conference, participants presented and exchanged opinions on Chinese drug regulation in the new era, strategies of major pharmaceutical companies in China, and a review of biomedical investments and financings in the United States and Europe.

Also at the conference, Bay City Capital and GF Xinde announced a new life sciences fund -- Bay City Capital GF Xinde International Life Sciences USD Fund, L.P., a Cayman Islands exempted limited partnership. This fund will invest in companies across all stages of development with a focus on novel and transformative biopharmaceutical investments including the United States, Canada, Western Europe and China. This unique collaboration between Bay City Capital and GF Xinde aims to capitalize on the strengths of Bay City Capital in deal sourcing and execution in the Western markets and GF Xinde's strategic network in China for value-add partnerships and financing opportunities for the fund. "China is the fastest growing life science market and is the world's second largest pharmaceutical market," said David Beier, Managing Director of Bay City Capital. "Our collaboration with GF Xinde can provide valuable insights for this important healthcare segment."
GF Xinde is a private equity investment subsidiary wholly owned by GF Securities, a large leading A+H share listed securities company whose clients comprise 80 percent of the listed pharmaceutical companies in China and which has deep connections to Chinese biotech and pharma industries. "The establishment of Bay City Capital GF Xinde International Life Sciences USD Fund is another important step in GF Xinde's China life science strategy. "Access to innovation is a high priority for Chinese companies and this fund will provide a window into cutting-edge technologies and assets in the United States and beyond and serve as a cross-border healthcare investment and technology-licensing portal for both foreign and Chinese healthcare companies," said Dr. Zeng Hao, Chairman of GF Xinde.
This press release is issued by Wonderful Sky Financial Group Limited on behalf of GF Securities Co., Ltd.
For further information, please contact:
Wonderful Sky Financial Group Limited
Ms. Jacqueline Wong /Ms. Rose Guo / Mr. Terry Zhu
Tel: (852) 3970 2177/ (852) 3641 1312/ (852) 3970 2282
Fax: (852) 2865 1638
Email: po@wsfg.hk / gfs@wsfg.hk
- ASIA TODAY News Global Distribution http://www.AsiaToday.com








Â 











Recent Articles



CDOT Launched the Mass Production of its First Batch of Full Screen (18:9) Module Products Nationwide 



EQS Group opens up further growth potential with its new whistleblowing solution - Expansion into the areas of Governance, Risk & Compliance (GRC) 



CNIT signs $1.1 million cloud-based ad terminal contract for Beiijing 



Laurel Hill Congratulates China Biologic Products, Inc. for Receiving Overwhelming Shareholder Support for its Redomicile from Delaware to the Cayman Islands at the Annual Meeting 



Union Medical Healthcare Wins 'Certificate of Merit' in 'Enterprising Hong Kong Brand Awards 2017' 



GF Xinde and Bay City Capital Co-Host Investment Conference and Announce Collaboration on Unique Fund 



TCL Multimedia Establishes Cross-boundary Collaboration with Tencent 



Guotai Junan International Becomes One of the First Overseas Institutions in Concluding the First Domestic Bond Transaction through Bond Connect 



LongiTech Smart Energy Disposing Non-core Businesses Rapidly Develops Smart Energy and Solar Energy Businesses 



Kerry Logistics Reaped Two Wins at 2017 AFLAS Awards Named Best 3PL and Best Logistics Service Provider - Air Freight 







 


Â 












































 
 

 





















 
 




















 
 




 








 













SEE ALL


















Leading fintech firm to build top global mobile wallet clearance and settlement system






Jul 26, 2017






Global industry gathering to be held in the worldâ€™s largest  gas consuming AND gas producing country






Jul 26, 2017






CDOT Launched the Mass Production of its First Batch of Full Screen (18:9) Module Products Nationwide






Jul 26, 2017






NKF Malaysia holds 13th Patient Forum for Dialysis Patients & Their Caregivers






Jul 26, 2017






parts2clean 2017 - Right on track with new special exhibition and high exhibitor numbers






Jul 25, 2017






National challenges: need for affordable and accessible homes take focus on the road to the 6th Asia-Pacific Housing Forum






Jul 25, 2017






EQS Group opens up further growth potential with its new whistleblowing solution - Expansion into the areas of Governance, Risk & Compliance (GRC)






Jul 25, 2017






CNIT signs $1.1 million cloud-based ad terminal contract for Beiijing






Jul 25, 2017






 






Submit News or Article 
               








 




















 
 




 
 
 





 


About Us

Contact Us

Term of Use



Publishers & Partners




Promote Events


365 Branding

Resources

ä»Šæ—¥äºšæ´²æ–°é—»

ä»Šæ—¥äºæ´²æ–°è





 



Â© 2017  ASIA TODAY
Â 





Â 





 




















 
 
 
 

Â 







GF Xinde and Bay City Capital Co-Host Investment Conference and Announce Collaboration on Unique Fund | ASIA TODAY News & Events















Â 

























 



 
 
 





 



 

PR NEWS


EVENTS

FEATURES

ECO & GREEN

EDUCATION

NONPROFIT

INNOVATION
 Â 


Log In

 Register







 



 Â  Â  Â EVENT Â 

 Listings
Â 
 Partners

Â 
 Newsletters
Â 
 Subscribe
Â 
 Submit Event
Â 
 Submit News
Â 





Search this site: 










Â 





 
 


 









GF Xinde and Bay City Capital Co-Host Investment Conference and Announce Collaboration on Unique Fund          





Â 












Jul 14, 2017



            Category: InvestmentPR News






















GF Securities, GF Xinde Investment Management Co., Ltd. ("GF Xinde") and Bay City Capital, LLC ("Bay City Capital"), in collaboration with the China Society of Biotechnology and the China Pharmaceutical Enterprises Development Promote Association, organized and hosted the 10th China Biotechnology Industry Conference - the Biomedical and Health Industry Investment and Financing Summit Forum. The conference was held on July 3 and 4 in the Guangzhou Baiyun International Convention Center in Guangzhou City, China.
The theme of the conference focused on the "Globalization of China's innovation and the Internationalization of regulation" in the biotechnology and biomedical industries. In addition, the conference covered the latest trends on cross-border biomedical investments and financings and bridging the technology gap between western technologies and domestic Chinese innovation.
Dr. Zeng Hao, Chairman of GF Xinde, Zhu Xun, Director of the Tongxieyi Innovative Drug Club, and David Beier JD, the Managing Director of Bay City Capital, were in attendance at the conference.
During the two-day conference, participants presented and exchanged opinions on Chinese drug regulation in the new era, strategies of major pharmaceutical companies in China, and a review of biomedical investments and financings in the United States and Europe.

Also at the conference, Bay City Capital and GF Xinde announced a new life sciences fund -- Bay City Capital GF Xinde International Life Sciences USD Fund, L.P., a Cayman Islands exempted limited partnership. This fund will invest in companies across all stages of development with a focus on novel and transformative biopharmaceutical investments including the United States, Canada, Western Europe and China. This unique collaboration between Bay City Capital and GF Xinde aims to capitalize on the strengths of Bay City Capital in deal sourcing and execution in the Western markets and GF Xinde's strategic network in China for value-add partnerships and financing opportunities for the fund. "China is the fastest growing life science market and is the world's second largest pharmaceutical market," said David Beier, Managing Director of Bay City Capital. "Our collaboration with GF Xinde can provide valuable insights for this important healthcare segment."
GF Xinde is a private equity investment subsidiary wholly owned by GF Securities, a large leading A+H share listed securities company whose clients comprise 80 percent of the listed pharmaceutical companies in China and which has deep connections to Chinese biotech and pharma industries. "The establishment of Bay City Capital GF Xinde International Life Sciences USD Fund is another important step in GF Xinde's China life science strategy. "Access to innovation is a high priority for Chinese companies and this fund will provide a window into cutting-edge technologies and assets in the United States and beyond and serve as a cross-border healthcare investment and technology-licensing portal for both foreign and Chinese healthcare companies," said Dr. Zeng Hao, Chairman of GF Xinde.
This press release is issued by Wonderful Sky Financial Group Limited on behalf of GF Securities Co., Ltd.
For further information, please contact:
Wonderful Sky Financial Group Limited
Ms. Jacqueline Wong /Ms. Rose Guo / Mr. Terry Zhu
Tel: (852) 3970 2177/ (852) 3641 1312/ (852) 3970 2282
Fax: (852) 2865 1638
Email: po@wsfg.hk / gfs@wsfg.hk
- ASIA TODAY News Global Distribution http://www.AsiaToday.com








Â 











Recent Articles



CDOT Launched the Mass Production of its First Batch of Full Screen (18:9) Module Products Nationwide 



EQS Group opens up further growth potential with its new whistleblowing solution - Expansion into the areas of Governance, Risk & Compliance (GRC) 



CNIT signs $1.1 million cloud-based ad terminal contract for Beiijing 



Laurel Hill Congratulates China Biologic Products, Inc. for Receiving Overwhelming Shareholder Support for its Redomicile from Delaware to the Cayman Islands at the Annual Meeting 



Union Medical Healthcare Wins 'Certificate of Merit' in 'Enterprising Hong Kong Brand Awards 2017' 



GF Xinde and Bay City Capital Co-Host Investment Conference and Announce Collaboration on Unique Fund 



TCL Multimedia Establishes Cross-boundary Collaboration with Tencent 



Guotai Junan International Becomes One of the First Overseas Institutions in Concluding the First Domestic Bond Transaction through Bond Connect 



LongiTech Smart Energy Disposing Non-core Businesses Rapidly Develops Smart Energy and Solar Energy Businesses 



Kerry Logistics Reaped Two Wins at 2017 AFLAS Awards Named Best 3PL and Best Logistics Service Provider - Air Freight 







 


Â 












































 
 

 





















 
 




















 
 




 








 













SEE ALL


















Leading fintech firm to build top global mobile wallet clearance and settlement system






Jul 26, 2017






Global industry gathering to be held in the worldâ€™s largest  gas consuming AND gas producing country






Jul 26, 2017






CDOT Launched the Mass Production of its First Batch of Full Screen (18:9) Module Products Nationwide






Jul 26, 2017






NKF Malaysia holds 13th Patient Forum for Dialysis Patients & Their Caregivers






Jul 26, 2017






parts2clean 2017 - Right on track with new special exhibition and high exhibitor numbers






Jul 25, 2017






National challenges: need for affordable and accessible homes take focus on the road to the 6th Asia-Pacific Housing Forum






Jul 25, 2017






EQS Group opens up further growth potential with its new whistleblowing solution - Expansion into the areas of Governance, Risk & Compliance (GRC)






Jul 25, 2017






CNIT signs $1.1 million cloud-based ad terminal contract for Beiijing






Jul 25, 2017






 






Submit News or Article 
               








 




















 
 




 
 
 





 


About Us

Contact Us

Term of Use



Publishers & Partners




Promote Events


365 Branding

Resources

ä»Šæ—¥äºšæ´²æ–°é—»

ä»Šæ—¥äºæ´²æ–°è





 



Â© 2017  ASIA TODAY
Â 





Â 





 




















 
 
 
 

Â 




GF Xinde and Bay City Capital Co-Host Investment Conference and Announce Collaboration on Unique FundHomeMailFlickrTumblrNewsSportsFinanceCelebrityAnswersGroupsMobileMoreTry Yahoo Finance on FirefoxÂ Â»YahooSearchSearchSign inU.S. Markets closedS&P 5002,477.83+0.70 (+0.03%)Dow 3021,711.01+97.58 (+0.45%)Nasdaq6,422.75+10.57 (+0.16%)LISTENTop economists debate state of labor marketYahoo Finance's Nicole Sinclair moderates a panel of leading economists at the State of the Labor Market SummitGF Xinde and Bay City Capital Co-Host Investment Conference and Announce Collaboration on Unique FundNewsfile Corp.NewsfileJuly 10, 2017ReblogShareTweetShareNew York, New York--(Newsfile Corp. - July 9, 2017) - GF Securities, GF Xinde Investment Management Co., Ltd. ("GF Xinde") and Bay City Capital, LLC ("Bay City Capital"), in collaboration with the China Society of Biotechnology and the China Pharmaceutical Enterprises Development Promote Association, organized and hosted the 10th China Biotechnology Industry Conference - the Biomedical and Health Industry Investment and Financing Summit Forum. The conference was held on July 3 and 4 in the Guangzhou Baiyun International Convention Center in Guangzhou City, China.The theme of the conference focused on the "Globalization of China's innovation and the Internationalization of regulation" in the biotechnology and biomedical industries. In addition, the conference covered the latest trends on cross-border biomedical investments and financings and bridging the technology gap between western technologies and domestic Chinese innovation.Dr. Zeng Hao, Chairman of GF Xinde, Zhu Xun, Director of the Tongxieyi Innovative Drug Club, and David Beier JD, the Managing Director of Bay City Capital, were in attendance at the conference.During the two-day conference, participants presented and exchanged opinions on Chinese drug regulation in the new era, strategies of major pharmaceutical companies in China, and a review of biomedical investments and financings in the United States and Europe.Also at the conference, Bay City Capital and GF Xinde announced a new life sciences fund -- Bay City Capital GF Xinde International Life Sciences USD Fund, L.P., a Cayman Islands exempted limited partnership. This fund will invest in companies across all stages of development with a focus on novel and transformative biopharmaceutical investments including the United States, Canada, Western Europe and China. This unique collaboration between Bay City Capital and GF Xinde aims to capitalize on the strengths of Bay City Capital in deal sourcing and execution in the Western markets and GF Xinde's strategic network in China for value-add partnerships and financing opportunities for the fund. "China is the fastest growing life science market and is the world's second largest pharmaceutical market," said David Beier, Managing Director of Bay City Capital. "Our collaboration with GF Xinde can provide valuable insights for this important healthcare segment."GF Xinde is a private equity investment subsidiary wholly owned by GF Securities, a large leading A+H share listed securities company whose clients comprise 80 percent of the listed pharmaceutical companies in China and which has deep connections to Chinese biotech and pharma industries. "The establishment of Bay City Capital GF Xinde International Life Sciences USD Fund is another important step in GF Xinde's China life science strategy. "Access to innovation is a high priority for Chinese companies and this fund will provide a window into cutting-edge technologies and assets in the United States and beyond and serve as a cross-border healthcare investment and technology-licensing portal for both foreign and Chinese healthcare companies," said Dr. Zeng Hao, Chairman of GF Xinde.This press release is issued by Wonderful Sky Financial Group Limited on behalf of GF Securities Co., Ltd.For further information, please contact:Wonderful Sky Financial Group LimitedMs. Jacqueline Wong /Ms. Rose Guo / Mr. Terry ZhuTel: (852) 3970 2177/ (852) 3641 1312/ (852) 3970 2282Fax: (852) 2865 1638Email: po@wsfg.hk / gfs@wsfg.hkReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextChina and India are edging closer to a war in Asia that neither can back down fromBusiness Insider UKEngineer Finds Pattern; Makes Millions in StocksMoney MorningSponsoredChina's army looks like it's getting ready for something big to go down in North KoreaBusiness Insider UKAs India and China face off in the mountains, a new confrontation is growing in the oceanCNBCChina urges US to stop 'unfriendly' recon flightsAFPWomen Everywhere Should Carry This Tiny DeviceSiren SongSponsoredChina is strengthening its military presence along the borders with North Korea and IndiaNewsweekKristin Beck, transgender Navy SEAL hero: 'Let's meet face to face and you tell me I'm not worthy'Business InsiderHighest ranking retired transgender officer slams new plan: I think Trump is â€˜being influenced by Penceâ€™Business InsiderDiscover it: 4.8 out of 5 avg. by 24K+ customersDiscover CardSponsoredFacebook results beat estimates as mobile ad sales soar, stock at record highReutersAdvanced Micro Devices Could Gain Another 17% Within Hours: ChartThe StreetAmazonâ€™s Echo rivaled by Xiaomi and Facebook: rptYahoo Finance VideoStart Earning Miles With The Best Travel CardWise BreadSponsoredMoney Basics: What is a hedge fund?Yahoo FinanceWhite House press secretary threatens to end briefing amid grilling over Trump's transgender banBusiness InsiderSens. McCain and Ernst, both veterans, oppose Trumpâ€™s ban on transgender military serviceC: Americans should not have to pay for anyone's reassignment surgery.
Certainly not the military!Join the Conversation1 / 52.6k



















Â 




Bay City Capital GF Xinde International Life Sciences USD Fund, L.P. - Who is raising money? | SEC filings of fundraisings and investments in hedge funds, startups and private equity companies















Who is raising money?











Bay City Capital GF Xinde International Life Sciences USD Fund, L.P.  Funding details


Bay City Capital GF Xinde International Life Sciences USD Fund, L.P. Industry: Pooled Investment FundCIK Number: 0001683312IRS Number: 981291456Address: UGLAND HOUSE, P.O. BOX 309  GRAND CAYMAN KY1-1104Phone number: 415-676-3830



Bay City Capital GF Xinde International Life Sciences USD Fund, L.P. Filings

DateFiling TypeOfferedSoldRemainingMin. investmentInvest. countExemption / Exlusions
2016-11-02New Form D$200,000,000Yet To Sell$200,000,000$0006b 3C 3C.1[SECÂ Filing]



Directors and Executives of Bay City Capital GF Xinde International Life Sciences USD Fund, L.P.
Key People in Bay City Capital GF Xinde International Life Sciences USD Fund, L.P.:

N/A Bay City Capital GF XINDE Investment Management CoDavid BeierFrederick CravesXuesheng XiaoXiaomin AoYongyuan Xie
Similar companiesBay Pond Partners, L.P., Bay Equity LLC, BAY NATIONAL CORP, Bay Bridge TMT Value Fund, L.P., BAYLAKE CORP, Bayhill Therapeutics, Inc., BAY VIEW PARTNERS LLC, Bayru, LLC, Bay State Surgical Services, LLC, Bayview Opportunity Domestic IIa, L.P., Bayview Opportunity Offshore IIa, L.P., Bay Area Partners, Ltd.








Last visited companies: Washington Economic Recovery Fund, Inc, WHIPPOORWILL DISTRESSED OPPORTUNITY FUND L P, Whippoorwill Offshore Distressed Opportunity Fund, Ltd., Whitecliff/EmpowerMX LP, Adcore Capital Inc

								Â© whoisraisingmoney.com
Daily updated news about investment into startups, hedge funds and private equity companies.
















Bay City Capital GF Xinde International Life Sciences USD Fund, L.P., BizPedia.xyz - We monitor changes in companies





















BizPedia.xyz  - We monitor changes in companies
 






Bay City Capital GF Xinde International Life Sciences USD Fund, L.P.


FREE EMAIL WATCHDOG
Get free email notifications about news in Bay City Capital GF Xinde International Life Sciences USD Fund, L.P..










The service is free and you can unsubscribe at any time.

General | People (6) | Filings (1) | Investment rounds (1)
CIK Number: 0001683312IRS Number: 981291456Bay City Capital GF Xinde International Life Sciences USD Fund, L.P. is on the market less than 5 years.

Bay City Capital GF Xinde International Life Sciences USD Fund, L.P. addressUGLAND HOUSE, P.O. BOX 309GRAND CAYMAN KY1-1104
Company jurisdiction
CAYMAN ISLANDS  
  Entity type
Cayman Islands exempted limited partnership 
Earliest known filing
November 2016
Latest known filing
November 2016




Company filings
SEC filings are a great source of information for companies including investments, company events, and all sorts of other information. 
Bay City Capital GF Xinde International Life Sciences USD Fund, L.P. has 1 filings. View Bay City Capital GF Xinde International Life Sciences USD Fund, L.P. filings.
Investment RoundsBay City Capital GF Xinde International Life Sciences USD Fund, L.P. recieved 1 investments.
PeopleWe have found 6 people related to Bay City Capital GF Xinde International Life Sciences USD Fund, L.P..
Similar companiesBAY STATE GAS CO /NEW/, BAYBANKS INC, BAY AREA HOLDINGS INC, BAYLAKE CORP, BAYTIDE SECURITIES CORPORATION, BAYPORT RESTAURANT GROUP INC, BAY AREA BANCSHARES, BAY COMMERCIAL SERVICES, BAYOU STEEL CORP, BAY PARTNERS IV, BAY NETWORKS INC /DE/, BAYLAKE BANK                                            /TA, BAY STREET ASSOCIATES LTD, BAY BANCORP, INC., BAYFUNDS, BAYFIELD LOW INCOME HOUSING LIMITED PARTNERSHIP, BAY NETWORKS INC, BAYBERRY WEST PARTNERS L P, BAY RESOURCE PARTNERS LP, BAYBANK /MA/, BAY RIDGE BANCORP INC, BAYVIEW YACHT CLUB INC, BAY BANKS SAVINGS PROFIT SHARING & STOCK OWERSHIP TRUST, BAYERISCHE HYPOTHEKEN UND WECHSEL BANK AG /FI/, BAYHAWK ALES INC, BAY AREA WAREHOUSE STORES INC, BAYER AG /FI, Bay Pond Partners, L.P., BAYSTATE CAPITAL SERVICES, INC., BAYLOR COLLEGE OF MEDICINE, BAY COMMERCIAL SERVICES EMPLOYEE STOCK OWNERSHIP PLAN, BAYLEY FRANK S, BAY HARBOUR 90-1 LTD, BAYOU SECURITIES LLC                                    /BD, BAY CREST PARTNERS, LLC, BAYER CORP, BAYSIDE DEVELOPMENT CORP, BAYVIEW INVESTORS LTD, BAYCORP HOLDINGS LTD, BAY ISLE FINANCIAL CORP, BAYER RICHARD A, BAYLOR HAROLD A JR, BAYLESS JON W, BAY VIEW SECURITIZATION CORP, BAYLOR UNIVERSITY MEDICAL CENTER, BAYSIDE FINANCIAL CORP, BAYERN STEVEN, BAYLESS JON W INC, BAY POND INVESTORS BERUMDA L P, BAY BANKS OF VIRGINIA INC














BizPedia.xyz collect news, financial information, SEC filings, stock information, contact information, personal information, information about investments, etc. about Bay City Capital GF Xinde International Life Sciences USD Fund, L.P.. 







Bay City Capital GF Xinde International Life Sciences USD Fund, L.P. $200,000,000 Financing | Newest SEC Filings

















Newest Filings











Bay City Capital GF Xinde International Life Sciences USD Fund, L.P. $200,000,000 Financing
Bay City Capital GF Xinde International Life Sciences USD Fund, L.P. just submitted form D announcing $200,000,000 financing.  This is a new filing. Bay City Capital GF Xinde International Life Sciences USD Fund, L.P. was able to sell $0. That is 0% of the round of financing. The total private offering amount was $200,000,000. The financing was made by 0 investors. Minimal accepted investment was $0. The financing document was filed on 2016-11-02. Bay City Capital GF Xinde International Life Sciences USD Fund, L.P. is based in  UGLAND HOUSE, P.O. BOX 309  GRAND CAYMAN KY1-1104. The firm's business is Pooled Investment Fund. The firm's revenue range is Decline to Disclose. The form was signed by  N/A Bay City Capital GF XINDE Investment Management Co.





SEC FORM D


The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.The reader should not assume that the information is accurate and complete.



UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORM DNotice of Exempt Offering of Securities


OMB APPROVAL


OMB Number:
3235-0076

Estimated average burden

hours per response:
4.00






1. Issuer's Identity


CIK (Filer ID Number)
Previous Names

X
None

Entity Type


0001683312




Â Â 
Corporation


Â Â 
Limited Partnership


Â Â 
Limited Liability Company


Â Â 
General Partnership


Â Â 
Business Trust


X
Other (Specify)


Cayman Islands exempted limited partnership

Name of Issuer
Bay City Capital GF Xinde International Life Sciences USD Fund, L.P.
Jurisdiction of Incorporation/Organization
CAYMAN ISLANDS
Year of Incorporation/Organization


Â Â 
Over Five Years Ago


X
Within Last Five Years (Specify Year)
2016


Â Â 
Yet to Be Formed



2. Principal Place of Business and Contact Information

Name of Issuer
Bay City Capital GF Xinde International Life Sciences USD Fund, L.P.

Street Address 1
Street Address 2

UGLAND HOUSE, P.O. BOX 309

City
State/Province/Country
ZIP/PostalCode
Phone Number of Issuer


GRAND CAYMAN
CAYMAN ISLANDS
KY1-1104
415-676-3830


3. Related Persons


Last Name
First Name
Middle Name


Bay City Capital GF XINDE Investment Management Co
N/A
N/A


Street Address 1
Street Address 2


750 Battery Street
Suite 400


City
State/Province/Country
ZIP/PostalCode


San Francisco
CALIFORNIA
94111



Relationship:
Â Â 
Executive Officer
Â Â 
Director
X
Promoter

Clarification of Response (if Necessary):
The General Partner of the Issuer


Last Name
First Name
Middle Name


Beier
David
William


Street Address 1
Street Address 2


750 Battery Street
Suite 400


City
State/Province/Country
ZIP/PostalCode


San Francisco
CALIFORNIA
94111



Relationship:
Â Â 
Executive Officer
X
Director
X
Promoter

Clarification of Response (if Necessary):
Director of the General Partner


Last Name
First Name
Middle Name


Craves
Frederick
Bernard


Street Address 1
Street Address 2


750 Battery Street
Suite 400


City
State/Province/Country
ZIP/PostalCode


San Francisco
CALIFORNIA
94111



Relationship:
Â Â 
Executive Officer
X
Director
X
Promoter

Clarification of Response (if Necessary):
Director of the General Partner


Last Name
First Name
Middle Name


Xiao
Xuesheng


Street Address 1
Street Address 2


16th Floor, No. 183 Tianhe North Road
Tianhe District


City
State/Province/Country
ZIP/PostalCode


Guangzhou, Guangdong
CHINA
510620



Relationship:
Â Â 
Executive Officer
X
Director
X
Promoter

Clarification of Response (if Necessary):
Director of the General Partner


Last Name
First Name
Middle Name


Ao
Xiaomin


Street Address 1
Street Address 2


16th Floor, No. 183 Tianhe North Road
Tianhe District


City
State/Province/Country
ZIP/PostalCode


Guangzhou, Guangdong
CHINA
510620



Relationship:
Â Â 
Executive Officer
X
Director
X
Promoter

Clarification of Response (if Necessary):
Director of the General Partner


Last Name
First Name
Middle Name


Xie
Yongyuan


Street Address 1
Street Address 2


16th Floor, No. 183 Tianhe North Road
Tianhe District


City
State/Province/Country
ZIP/PostalCode


Guangzhou, Guangdong
CHINA
510620



Relationship:
Â Â 
Executive Officer
X
Director
X
Promoter

Clarification of Response (if Necessary):
Director of the General Partner
4. Industry Group



Â Â 
Agriculture



Banking & Financial Services





Â Â 
Commercial Banking


Â Â 
Insurance


Â Â 
Investing


Â Â 
Investment Banking


X
Pooled Investment Fund





Â Â 
Hedge Fund


Â Â 
Private Equity Fund


X
Venture Capital Fund


Â Â 
Other Investment Fund





Is the issuer registered as an investment company under the Investment Company Act of 1940? 




Â Â 
Yes
X
No



Â Â 
Other Banking & Financial Services




Â Â 
Business Services



Energy




Â Â 
Coal Mining





Â Â 
Electric Utilities





Â Â 
Energy Conservation





Â Â 
Environmental Services





Â Â 
Oil & Gas





Â Â 
Other Energy






Health Care




Â Â 
Biotechnology





Â Â 
Health Insurance





Â Â 
Hospitals & Physicians





Â Â 
Pharmaceuticals





Â Â 
Other Health Care



Â Â 
Manufacturing



Real Estate




Â Â 
Commercial





Â Â 
Construction





Â Â 
REITS & Finance





Â Â 
Residential





Â Â 
Other Real Estate





Â Â 
Retailing


Â Â 
Restaurants



Technology




Â Â 
Computers





Â Â 
Telecommunications





Â Â 
Other Technology




Travel




Â Â 
Airlines & Airports





Â Â 
Lodging & Conventions





Â Â 
Tourism & Travel Services





Â Â 
Other Travel



Â Â 
Other



5. Issuer Size










Revenue Range
OR
Aggregate Net Asset Value Range


Â Â 
No Revenues
Â Â 
No Aggregate Net Asset Value


Â Â 
$1 - $1,000,000
Â Â 
$1 - $5,000,000


Â Â 
$1,000,001 - $5,000,000
Â Â 
$5,000,001 - $25,000,000


Â Â 
$5,000,001 - $25,000,000
Â Â 
$25,000,001 - $50,000,000


Â Â 
$25,000,001 - $100,000,000
Â Â 
$50,000,001 - $100,000,000


Â Â 
Over $100,000,000
Â Â 
Over $100,000,000


X
Decline to Disclose
Â Â 
Decline to Disclose


Â Â 
Not Applicable
Â Â 
Not Applicable



6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)



Â Â 
Rule 504(b)(1) (not (i), (ii) or (iii))


Â Â 
Rule 504 (b)(1)(i)


Â Â 
Rule 504 (b)(1)(ii)


Â Â 
Rule 504 (b)(1)(iii)


Â Â 
Rule 505


X
Rule 506(b)


Â Â 
Rule 506(c)


Â Â 
Securities Act Section 4(a)(5)




X
Investment Company Act Section 3(c)


X
Section 3(c)(1)
Â Â 
Section 3(c)(9)Â Â 


Â Â 
Section 3(c)(2)
Â Â 
Section 3(c)(10)


Â Â 
Section 3(c)(3)
Â Â 
Section 3(c)(11)


Â Â 
Section 3(c)(4)
Â Â 
Section 3(c)(12)


Â Â 
Section 3(c)(5)
Â Â 
Section 3(c)(13)


Â Â 
Section 3(c)(6)
Â Â 
Section 3(c)(14)


Â Â 
Section 3(c)(7)



7. Type of Filing


X
New Notice

Date of First Sale

X
First Sale Yet to Occur


Â Â 
Amendment


8. Duration of Offering

Does the Issuer intend this offering to last more than one year?


Â Â 
Yes
X
No


9. Type(s) of Securities Offered (select all that apply)









Â Â 
Equity
X
Pooled Investment Fund Interests


Â Â 
Debt
Â Â 
Tenant-in-Common Securities


Â Â 
Option, Warrant or Other Right to Acquire Another Security
Â Â 
Mineral Property Securities


Â Â 
Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security
Â Â 
Other (describe)







10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?


Â Â 
Yes
X
No


Clarification of Response (if Necessary):
11. Minimum Investment

Minimum investment accepted from any outside investor

$0

USD

12. Sales Compensation


Recipient

Recipient CRD Number
X
None




(Associated) Broker or Dealer
X
None


(Associated) Broker or Dealer CRD Number
X
None



Street Address 1
Street Address 2


City
State/Province/Country
ZIP/Postal Code



State(s) of Solicitation (select all that apply)Check â€œAll Statesâ€ or check individual States
Â Â 
All States


Â Â 
Foreign/non-US



13. Offering and Sales Amounts


Total Offering Amount

$200,000,000

USD

or
Â Â 
Indefinite



Total Amount Sold

$0

USD


Total Remaining to be Sold

$200,000,000

USD

or
Â Â 
Indefinite



Clarification of Response (if Necessary):
14. Investors


Â Â 
Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.




Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
0


15. Sales Commissions & Finder's Fees Expenses
Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.


Sales Commissions

$0

USD

Â Â 
Estimate



Finders' Fees

$0

USD

Â Â 
Estimate



Clarification of Response (if Necessary):
16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.



$0

USD

Â Â 
Estimate


Clarification of Response (if Necessary):
The Issuer's General Partner (or its designee) is entitled to a management fee payable by the Issuer.Signature and Submission
Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.
Terms of Submission

In submitting this notice, each issuer named above is:

Notifying the SEC and/or each State in which this notice is filed of the offering of 
                    securities described and undertaking to furnish them, upon written request, in the accordance with applicable
                    law, the information furnished to offerees.*
Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator 
                    or other legally designated officer of the State in which the issuer maintains its principal 
                    place of business and any State in which this notice is filed, as its agents for service of 
                    process, and agreeing that these persons may accept service on its behalf, of any notice, 
                    process or pleading, and further agreeing that such service may be made by registered or 
                    certified mail, in any Federal or state action, administrative proceeding, or arbitration 
                    brought against it in any place subject to the jurisdiction of the United States, if the 
                    action, proceeding or arbitration (a) arises out of any activity in connection with the 
                    offering of securities that is the subject of this notice, and (b) is founded, directly or 
                    indirectly, upon the provisions of:Â  (i) the Securities Act of 1933, the Securities Exchange 
                    Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the 
                    Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) 
                    the laws of the State in which the issuer maintains its principal place of business or any State 
                    in which this notice is filed.
Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).


Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.
For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.


Issuer
Signature
Name of Signer
Title
Date


Bay City Capital GF Xinde International Life Sciences USD Fund, L.P.
/s/ Frederick Bernard Craves
Frederick Bernard Craves
Director of the General Partner
2016-11-02


Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
* This undertaking does not affect any limits Section 102(a) of the National Securities Markets
        Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to
        require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes 
        of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot
        routinely require offering materials under this undertaking or otherwise and can require offering materials only to the
        extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.




Bay City Capital GF Xinde International Life Sciences USD Fund, L.P. Financing

DateFiling TypeOfferedSoldRemainingMin. investmentInvest. countExemption / Exlusions
2016-11-02New Form D$200,000,000Yet To Sell$200,000,000$0006b 3C 3C.1[view]
Bay City Capital GF Xinde International Life Sciences USD Fund, L.P. List of ExecutivesDavid Beier, Frederick Craves, N/A Bay City Capital GF XINDE Investment Management Co, Xiaomin Ao, Xuesheng Xiao, Yongyuan Xie











Last visited: Elementum Directus Onshore Fund LP, Elevation Real Property Fund V, LLC, Elicit, Inc., Elk Homes Partners II LP, Ellipsis Technologies Inc.

								Â© 
							


















Bay City Capital GF Xinde International Life Sciences USD Fund, L.P. - Pooled Investment Fund- Ao  FormDs.com - SEC filings of fundraisings and investments in hedge funds, private equity firms, startups, and growing companies 











 FormDs.com 





 Newest
 Filter
 Local




 









Bay City Capital GF Xinde International Life Sciences USD Fund, L.P.

      Industry: Pooled Investment Fund
      (See others in industry)

Address:



    Ugland House, P.O. Box 309  
    Grand Cayman, E9, KY1-1104Phone: 415-676-3830 




Filings



Date
FilingType
Reported Sold
Incremental Cash 
Type
Exemptions
Link to Raw Filing




	2016-11-02


New


Yet to Sell


$0


Other


06b 3C 3C.1


SEC link






Directors and Executives (Current and Past)



Name
Role



 Xiaomin Ao 
 Director, Promoter 


 N/A N/A Bay City Capital Gf Xinde Investment Management Co 
 Promoter 


 David William Beier 
 Director, Promoter 


 Frederick Bernard Craves 
 Director, Promoter 


 Xuesheng Xiao 
 Director, Promoter 


 Yongyuan Xie 
 Director, Promoter 












Bay City Capital GF Xinde International Life Sciences USD Fund, L.P. - List of CEOs, founders and company directors

















directorpedia.net - List of CEOs, founders, board members and company directors











Bay City Capital GF Xinde International Life Sciences USD Fund, L.P.
List of persons related to the company Bay City Capital GF Xinde International Life Sciences USD Fund, L.P.. Find out list of CEOs, founders, board members, and company directors of Bay City Capital GF Xinde International Life Sciences USD Fund, L.P..

CIK Number: 0001683312IRS Number: 981291456Company address: UGLAND HOUSE, P.O. BOX 309  GRAND CAYMAN KY1-1104Phone number: 415-676-3830



People related to Bay City Capital GF Xinde International Life Sciences USD Fund, L.P.
NamePositionStreetCityCountryWilliam Beier  David750 Battery Street Suite 400San FranciscoCAB Craves  Frederick750 Battery Street Suite 400San FranciscoCAN/A Bay City Capital GF XINDE Investment Management Co  N/A750 Battery Street Suite 400San FranciscoCAAo  Xiaomin16th Floor, No. 183 Tianhe North Road Tianhe DistrictGuangzhou, GuangdongChinaXiao  Xuesheng16th Floor, No. 183 Tianhe North Road Tianhe DistrictGuangzhou, GuangdongChinaXie  Yongyuan16th Floor, No. 183 Tianhe North Road Tianhe DistrictGuangzhou, GuangdongChina




Bay City Capital GF Xinde International Life Sciences USD Fund, L.P. on the Web
Related companiesBay Acquisition Corp., Bay Area & Pacific Coast Development, Limited Partnership, Bay Area & Pacific Coast Development, Inc., Bay Area 14 Fund, LLC, Bay Area 16 Fund, LLC, Bay Area Accountable Care Network, Inc., Bay Area Hospital Real Estate, LLC, Bay Area Partners, Ltd., Bay Area Regional Medical Center, LLC, Bay Avenue Long-Short Investment Fund I, LLC, Bay Avenue Private Opportunities Fund, LLC, BAY BANCORP, INC., BAY BANKS OF VIRGINIA INC, Bay Bridge TMT Value Fund, L.P., Bay Capital Feeder Fund Ltd.












 








GF Xinde and Bay City Capital Co-Host Investment Conference and Announce Collaboration on Unique Fund




































Â 
Â 
Â 
Â 


HomeNewsFileXBRLPrintingAbout NewsfileCareersContactä¸­æ–‡FranÃ§ais


















	Â 
	
	Â  















GF Xinde and Bay City Capital Co-Host Investment Conference and Announce Collaboration on Unique Fund

New York, New York--(Newsfile Corp. - July 9, 2017) - GF Securities, GF Xinde Investment Management Co., Ltd. ("GF Xinde") and Bay City Capital, LLC ("Bay City Capital"), in collaboration with the China Society of Biotechnology and the China Pharmaceutical Enterprises Development Promote Association, organized and hosted the 10th China Biotechnology Industry Conference - the Biomedical and Health Industry Investment and Financing Summit Forum. The conference was held on July 3 and 4 in the Guangzhou Baiyun International Convention Center in Guangzhou City, China.The theme of the conference focused on the "Globalization of China's innovation and the Internationalization of regulation" in the biotechnology and biomedical industries. In addition, the conference covered the latest trends on cross-border biomedical investments and financings and bridging the technology gap between western technologies and domestic Chinese innovation.Dr. Zeng Hao, Chairman of GF Xinde, Zhu Xun, Director of the Tongxieyi Innovative Drug Club, and David Beier JD, the Managing Director of Bay City Capital, were in attendance at the conference.During the two-day conference, participants presented and exchanged opinions on Chinese drug regulation in the new era, strategies of major pharmaceutical companies in China, and a review of biomedical investments and financings in the United States and Europe.Also at the conference, Bay City Capital and GF Xinde announced a new life sciences fund -- Bay City Capital GF Xinde International Life Sciences USD Fund, L.P., a Cayman Islands exempted limited partnership. This fund will invest in companies across all stages of development with a focus on novel and transformative biopharmaceutical investments including the United States, Canada, Western Europe and China. This unique collaboration between Bay City Capital and GF Xinde aims to capitalize on the strengths of Bay City Capital in deal sourcing and execution in the Western markets and GF Xinde's strategic network in China for value-add partnerships and financing opportunities for the fund. "China is the fastest growing life science market and is the world's second largest pharmaceutical market," said David Beier, Managing Director of Bay City Capital. "Our collaboration with GF Xinde can provide valuable insights for this important healthcare segment."GF Xinde is a private equity investment subsidiary wholly owned by GF Securities, a large leading A+H share listed securities company whose clients comprise 80 percent of the listed pharmaceutical companies in China and which has deep connections to Chinese biotech and pharma industries. "The establishment of Bay City Capital GF Xinde International Life Sciences USD Fund is another important step in GF Xinde's China life science strategy. "Access to innovation is a high priority for Chinese companies and this fund will provide a window into cutting-edge technologies and assets in the United States and beyond and serve as a cross-border healthcare investment and technology-licensing portal for both foreign and Chinese healthcare companies," said Dr. Zeng Hao, Chairman of GF Xinde.This press release is issued by Wonderful Sky Financial Group Limited on behalf of GF Securities Co., Ltd.For further information, please contact:Wonderful Sky Financial Group LimitedMs. Jacqueline Wong /Ms. Rose Guo / Mr. Terry ZhuTel: (852) 3970 2177/ (852) 3641 1312/ (852) 3970 2282Fax: (852) 2865 1638Email: po@wsfg.hk / gfs@wsfg.hk




















Follow @newsfile_corp 





Jyn Erso 2017 ğŸ‡ºğŸ‡¸@JynErso_2017

20 s


@_disciple @R2D2_Resist @EzraBridger2017 @TheSWPrincess @morethanmySLE @Minervasbard @jetpaxNdemocraCâ€¦ https://t.co/BTFhRRc3sj









James Pollard@jamespollard97

27 s


The military is here for war and defense. The military hasn't cared for feelings since 1776 ğŸ‡ºğŸ‡¸









Rough-Soul@Rough_1776_Soul

1 m


RT @DailyCaller: COURT DOCS: Imran Awan Allegedly Threatened To Kidnap Stepmotherâ€™s Relatives If She Spoke To Cops https://t.co/BM1a0FeWPLâ€¦


















Company's News Releases

GF Xinde and Bay City Capital Co-Host Investment Conference and Announce Collaboration on Unique FundGF Securities' Dynamic Globalization Strategy 
Visit company's profile page 



 





		Copyright 2017 Newsfile Corp. All rights reserved.
Terms and Conditions of Use | Privacy Policy | Anti-Spam Policy | 
		Contact Us






GF Securities' Dynamic Globalization Strategy, GF Xinde Establishes Life Sciences Fund in the U.S. - dgap.de






















































MyWatchlist Login 
		
		
		|
		Kontakt

Â 



Realtime Mitteilungen


Kurse & Charts


Unternehmenscenter


Research


Erweiterte Suche


MyWatchlist


Die DGAP










Â 


Alle


Ad-hoc-Mitteilungen


Weitere Unternehmensmitteilungen


Ãœbernahmeangebote


Directors' Dealings


Stimmrechtsanteile


Gesamtstimmrechte


HV-Bekanntmachungen


Vorabbekanntmachung Finanzberichte


Sonstige Kapitalmarktinformationen


Zwischenmitteilungen


UK Regulatory


Internationale News


Â 

Â 





GF Securities Co., Ltd. (HK)
	
		
			GF Securities Co., Ltd. (HK)
					
		
	


ISIN: CNE100001TQ9
			

Land: China
			





			Nachricht vom 14.05.2016 | 04:59
		

GF Securities' Dynamic Globalization Strategy, GF Xinde Establishes Life Sciences Fund in the U.S. 





EQS-News / 14/05/2016 / 10:59 UTC+8


New York, U.S.                                                    May 13, 2016
/
GF Securities' Dynamic Globalization Strategy
GF Xinde Establishes Life Sciences Fund in the U.S.
 Recently, at New York Times Square the GF Securities' 25th anniversary promo video is airing on the China billboard downtown, 192 times a day. GF Securities is the largest, non-government, investment bank in China, listed on the Shenzhen and HK stock exchanges, in February 2010, and April 2015, respectively. The promotional display at Times Square in New York City is not only to create momentum for GF Xinde Investment Management CO., LTD. (a wholly owned subsidiary of GF Securities, hereinafter referred to as "GF Xinde", and to celebrate the creation of a Life Sciences Fund in the US; furthermore, it represents GF Securities overall strategic layout to acquire diversified assets including cutting-edge technology, laying a solid foundation for the company's overall strategy of increased globalization. 
 On May 13 (EDT), GF Xinde signed a strategic cooperation agreement in New York with Bay City Capital, America's leading life sciences investment institution for initiating the establishment of a multinational life sciences fund. Mr. Sun Shuming, Chairman of GF Securities attended the ceremony and declared that, "this life sciences fund is the first investment fund that combines 'international technology and Chinese backing!' This investment platform aims to break through innovative medical deficiencies in China, with advancements in life sciences technology representing a new era of creation and innovation. With more than 25 years of strategic planning and development, the pace of GF Securities international investments are gaining greater and greater traction. This is an unprecedented breakthrough in healthcare for GF Securities, to establish an international life sciences fund with the leading life sciences investment institution in the United States. It will provide momentum and innovative development resources for the Chinese life sciences industry! In terms of cross-industry and cross-border cooperation, this fund is an innovative first amongst Chinese investment banks."
 Mr. Fred Craves, founder and managing partner of Bay City Capital was in attendance during the ceremonial signing, and remarked, "Bay City Capital has invested in life sciences technology for nearly 20 years. And we feel honored to partner with GF Securities and GF Xinde. We have been interested with great intensity in the Chinese markets, closely following the initiatives put forth by the Chinese government for improving the quality and accessibility of universal health care. The current speed of development in China's pharmaceutical industry is much higher than that of Europe and America, thus the country is expected to become the world's largest pharmaceutical market soon. This will provide many opportunities for international medical investment institutions to enter China. GF Securities, as one of China's leading investment banks, has a wealth of resources and experience in capital market operations, with a vast network of institutional clients. We are confident that the cooperation between GF Xinde and Bay City Capital in an international life sciences fund will create outstanding financial and industrial benefits for Chinese enterprises."
 The fund, jointly managed by GF Xinde and Bay City Capital, focuses on investing in innovative life science companies with high growth potential in the United States, Europe and China. The fund will be fully backed by the resources of both Bay City Capital and GF Xinde to achieve cross-border mergers and acquisitions, which will serve to introduce the world's leading technology to Chinese enterprises. Chinese companies will gain access to competitive global products and technology. The fund will diversify sources of returns through a variety of exits channels, through cross-border mergers and acquisitions and the licensing of technology. 
 GF Securities and Bay City Capital, have already attracted large publicly listed pharmaceutical enterprises to be limited partners, including By Health, Jinling Aodong, Nanjing Pharma and Nanjing New Industry Investment Group which is major shareholder of Jinling Pharma, as well as publicly listed companies and institutions such as Solareast and Hengqin Financial Investment. There is a lack of leading-edge technology and innovative diversity in the pharmaceutical industry of China. In order to meet the demand for overseas mergers and acquisitions, now is a crucial time for Chinese pharmaceutical enterprises to carry out a large-scale reform of the pharmaceutical industry in China. Strong reform and supply side development in this industry, will have profound social effects for the entire Chinese society. 
 GF Xinde is China's leading PE and VC investment institution in China. Since its establishment, over the past eight years, the Company has ranked top three for direct investment five years in a row. Assets under management are more than RMB 15 billion, specializing in VC investment in life sciences, listed pharmaceutical companies, cross-border investment banking, IPO and M & As. In the field of life sciences, GF Xinde and GF Securities has a team of over 50 investment advisors, investment bankers and equity analysts. In addition, GF Xinde has a large presence in the health and medical industries, not only through direct investment holdings but facilitating merger and acquisitions of hospitals in China, and investing a considerable amount in various life sciences companies. GF Xinde has over 300 projects underway in the field of life science and the GF Xinde Medical Treatment Industry M&A Fund focuses on mergers and acquisitions of hospitals, with over 50 potential acquisition targets each year.
 Bay City Capital has been deeply involved in life sciences investment for over 20 years in the United States of America. It is the world's leading life sciences VC investment institution with a wealth of experience and resources in the R&D of pharmaceuticals and medical devices, IPOs and M&As, scientists and entrepreneurs. The Company has invested in more than 100 life sciences companies worldwide, with a successful exit rate of more than 50%.
-End-
This press release is issued by 
Wonderful Sky Financial Group Limited 
on behalf of GF Securities Co., Ltd.
For further information, please contact:
Wonderful Sky Financial Group Limited
Connie Liu / Barney Liu/ Sindy Wong
Tel:(852)3970 2290/ ï¼ˆ852ï¼‰3970 2212/ï¼ˆ852ï¼‰3970 2257
Email: po@wsfg.hk / barneyliu@wsfg.hk / sindywong@wsfg.hk



Document: http://n.eqs.com/c/fncls.ssp?u=XCHAFSQXKVDocument title: GF Securities' Dynamic Globalization Strategy, GF Xinde Establishes Life Sciences Fund in the U.S.


Key word(s): Miscellaneous

14/05/2016  Dissemination of a Press Release, transmitted by EQS TodayIR - a company of EQS Group AG.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com











Kurschart




Kursdetails anzeigen



Interaktiv




Weitere Unternehmensdetails





News per Mail erhalten





News aufs Handy erhalten





News empfehlen





News drucken





DGAP-Watchlist



E-Mail



Passwort




Passwort vergessen?


Â 


zur Registrierung



Ãœbersicht Indizes




weitere Indizes



Weitere News



weitere News anzeigen












                               GBC im Fokus
                






Fintech-Spezialist fÃ¼r den afrikanischen Markt

        


        
Das Fintech-Unternehmen MyBucks S.A. bietet den Kunden aus der Sub-Sahara-Region durch den Einsatz moderner Technologien einen Zugang zu Finanzprodukten- und dienstleistungen. Hierbei handelt es sich in erster Linie um nicht besicherte Kredite, welche Ã¼ber OnlinekanÃ¤le beantragt und in Anspruch genommen werden. Die Grundlage fÃ¼r die GeschÃ¤ftstÃ¤tigkeit stellt die selbstentwickelte Technologie dar, wodurch Kunden innerhalb weniger Minuten eine Kreditentscheidung erhalten. Wir gehen von einer Fortsetzung der dynamischen Unternehmensentwicklung aus und haben einen fairen Wert von 26,70 â‚¬ je Aktie und damit hohes Kurspotenzial ermittelt. Wir vergeben das Rating KAUFEN.




                                               Zur Studie
                               



Der AKTIONÃ„R News26. Juli 22:00 Neue Ausgabe: Bis zu 300% mit Blue Chips: HeiÃŸe Optionsschein-Wetten ...26. Juli 16:57 Barrick Gold, Newmont und Co vor dem Comeback?26. Juli 15:53 AMD: Bringen die Quartalszahlen den Turnaround?26. Juli 15:40 Hackeralarm bei Unicredit â€“ 400.000 Kunden betroffen26. Juli 15:34 Commerzbank: Das ist der Knaller!

News im Fokus





			Allianz SE: Allianz Gruppe steigert im 2Q 2017 operatives Ergebnis um 23 Prozent aufgrund von Verbesserungen in allen GeschÃ¤ftsbereichen; operatives Ergebnis des Gesamtjahres wird voraussichtlich das obere Ende der avisierten Zielspanne erreichen
		

			26. Juli 2017, 22:21
		


zur Meldung



Aktuelle Research-Studie

Original-Research: Solutions 30 SE (von Sphene Capital GmbH): Buy	Solutions 30 SE
26. Juli 2017


zur Research-Studie



Â 


DGAP â€“ ein Service der EQS Group AG

Twitter
		|
		Impressum
		|
		AGB
		|
		Rechtliche Hinweise & Datenschutz














